Vical Incorporated (VICL) 3.25 $VICL
Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 3:16PM CDT
Vical (VICL) and Astellas reported disappointing top-line phase II data on cytomegalovirus vaccine candidate, ASP0113, in kidney transplant patients.
VICL: 3.25 (+0.06), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)
Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients
GlobeNewswire - Mon Sep 19, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) and Astellas Pharma Inc. (TOKYO:4503) today announced topline results from a randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety and efficacy of cytomegalovirus (CMV) vaccine, ASP0113, versus placebo in kidney transplant patients receiving an organ from a CMV-seropositive donor. Results from the study demonstrated that the trial did not meet its primary endpoint, which was the proportion of patients having CMV viremia defined as a plasma viral load of greater-than or equal to 1000 IU/mL by central laboratory assay through one year after first injection of study drug. Additionally, the secondary endpoints of CMV-associated disease and CMV-specific antiviral therapy, which were evaluated by an independent, blinded Adjudication Committee, were similar in both treatment groups.
VICL: 3.25 (+0.06)
Vical to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Fri Sep 02, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Monday, September 12, at 11:40 a.m. ET at the 18 Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City. A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 3.25 (+0.06)
Vical Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three and six months ended June 30, 2016. Net loss for the second quarter of 2016 was $1.3 million, or $0.14 per share, compared with a net loss of $2.8 million, or $0.30 per share, for the second quarter of 2015. Revenues for the second quarter of 2016 were $4.1 million, compared with revenues of $4.2 million for the second quarter of 2015, reflecting revenues from Astellas Pharma Inc. for manufacturing services performed under the ASP0113 collaborative agreements. ASP0113 is Vical's therapeutic vaccine designed to prevent cytomegalovirus (CMV) disease and associated complications in transplant recipients.
VICL: 3.25 (+0.06)
Investor Calendar Invites You to the Vical Second Quarter 2016 Earnings Webcast Live on Tuesday, August 9, 2016
ACCESSWIRE - Mon Aug 08, 3:10PM CDT
SAN DIEGO, CA / ACCESSWIRE / August 8, 2016 / Vical Incorporated (NASDAQ: VICL) will host a live webcast to discuss the results of the second quarter 2016, to be held Tuesday, August 9, 2016 at 12:00 PM Eastern Time.
VICL: 3.25 (+0.06)
Vical Announces News Release and Conference Call Schedule for Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 02, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended June 30, 2016, before the opening of trading on Tuesday, August 9, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Tuesday, August 9. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
VICL: 3.25 (+0.06)
Vical Announces $7.8 Million Equity Investment by Partner, AnGes MG
GlobeNewswire - Mon Aug 01, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) announced an agreement by AnGes, MG, Vical's long-time partner and an existing shareholder, to purchase approximately $7.8 million of Vical's common stock in a private placement. The shares are being sold at a price of $4.24 per share, the 90-day volume weighted average price of Vical's common stock and a premium compared to the closing price on July 29. With the new investment, AnGes' equity position in Vical will increase from 2.4% to approximately 18.6% of Vical's outstanding shares. The private placement is expected to close on or about August 2, 2016, subject to the satisfaction or waiver of customary closing conditions.
VICL: 3.25 (+0.06)
Vical (VICL) Reports Phase I/II Data on Genital Herpes Vaccine
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:12AM CDT
Vical (VICL) presented data from a phase I/II study on its investigational genital herpes vaccine at a meeting of the American Society for Microbiology.
VICL: 3.25 (+0.06), ANIP: 66.64 (-0.17), PFE: 34.26 (+0.11), BMY: 56.48 (+0.06)
Vical's Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months
GlobeNewswire - Mon Jun 20, 10:15AM CDT
Vical Incorporated (Nasdaq:VICL) presented data from the randomized, double-blind, placebo-controlled Phase 1/2 clinical trial of its therapeutic genital herpes vaccine in symptomatic herpes simplex virus type 2 (HSV-2) infected patients in an oral late-breaker presentation at the American Society for Microbiology (ASM/ICAAC) Microbe 2016 meeting held in Boston. The slides presented by Mammen P. "Anza" Mammen, Jr., M.D., Vical's Vice President, Clinical Vaccines, will be accessible on Vical's website.
VICL: 3.25 (+0.06)
Vical to Present HSV-2 Phase 1/2 Data at June ASM Microbe/ICAAC 2016 Conference
GlobeNewswire - Mon Jun 13, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) announced today that the company will present clinical data on its completed HSV-2 Phase 1/2 trial at the American Society of Microbiology (ASM) Microbe/ICAAC 2016 conference (Boston, June 16 - 20).
VICL: 3.25 (+0.06)
Vical Provides VL-2397 Updates at BIO International Convention
GlobeNewswire - Tue May 31, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) announced today that the company will present an update on its investigational antifungal product candidate, VL-2397, at the BIO International Convention (San Francisco, June 6 - 9).
VICL: 3.25 (+0.06)
Vical reports 1Q loss
Automated Insights - Mon May 09, 5:36AM CDT
SAN DIEGO (AP) _ Vical Inc. (VICL) on Monday reported a loss of $2.4 million in its first quarter.
VICL: 3.25 (+0.06)
Vical Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 5:30AM CDT
ASP0113 Phase 3 Trial Enrollment Over 80% Complete
VICL: 3.25 (+0.06)
Investor Calendar Invites You to the Vical First Quarter 2016 Earnings Webcast Live on Monday, May 9, 2016
ACCESSWIRE - Fri May 06, 3:05PM CDT
SAN DIEGO, CA / ACCESSWIRE / May 6, 2016 / Vical Incorporated (NASDAQ: VICL) will host a live webcast to discuss the results of the first quarter 2016, to be held Monday, May 9, 2016 at 12:00 PM Eastern Time.
VICL: 3.25 (+0.06)
Vical Announces News Release and Conference Call Schedule for First Quarter 2016 Financial Results
GlobeNewswire - Mon May 02, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2016, before the opening of trading on Monday, May 9, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Monday, May 9. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
VICL: 3.25 (+0.06)
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/d53rgr/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus HHV-5 Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus HHV-5 Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cytomegalovirus HHV-5 Infections Overview - Therapeutics Development - Pipeline Products for Cytomegalovirus HHV-5 Infections - Overview - Pipeline Products for Cytomegalovirus HHV-5 Infections - Comparative Analysis - Cytomegalovirus HHV-5 Infections - Therapeutics under Development by Companies - Cytomegalovirus HHV-5 Infections - Therapeutics under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cytomegalovirus HHV-5 Infections - Products under Development by Companies - Cytomegalovirus HHV-5 Infections - Products under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Atara Biotherapeutics, Inc. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - China Biologic Products, Inc. - CyTuVax B.V. - GlaxoSmithKline Plc - Hookipa Biotech AG - Humabs BioMed SA - iQur Limited - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Savoy Pharmaceuticals, Inc. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/d5...egalovirus
CBPO: 126.09 (+0.87), VICL: 3.25 (+0.06), CMRX: 5.72 (-0.03), PFE: 34.26 (+0.11), MRK: 62.96 (-0.06), ATRA: 20.12 (-0.34), VBIV: 3.90 (+0.09), GSK: 43.42 (-0.16), NVS: 81.48 (-0.55)
Measles - World Therapeutics Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/7nr298/measles) has announced the addition of the "Measles - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Measles, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Measles and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Measles Overview - Therapeutics Development - Pipeline Products for Measles - Overview - Pipeline Products for Measles - Comparative Analysis - Measles - Therapeutics under Development by Companies - Measles - Therapeutics under Investigation by Universities/Institutes - Measles - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Measles - Products under Development by Companies - Measles - Products under Investigation by Universities/Institutes - Measles - Companies Involved in Therapeutics Development - Beijing Minhai Biotechnology Co., Ltd - Beijing Tiantan Biological Products Co., Ltd. - Biological E. Limited - China National Pharmaceutical Group Corporation - Daiichi Sankyo Company, Limited - GlaxoSmithKline Plc - Organic Vaccines - Prometheon Pharma, LLC - Sinovac Biotech Ltd. - Vical Incorporated - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/7nr298/measles
VICL: 3.25 (+0.06), GSK: 43.42 (-0.16), SVA: 5.81 (-0.06)
Aspergillosis Market Report - Global Therapeutics Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/lxqfdm/aspergillosis) has announced the addition of the "Aspergillosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Aspergillosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aspergillosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Aspergillosis Overview - Therapeutics Development - Pipeline Products for Aspergillosis - Overview - Pipeline Products for Aspergillosis - Comparative Analysis - Aspergillosis - Therapeutics under Development by Companies - Aspergillosis - Therapeutics under Investigation by Universities/Institutes - Aspergillosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Aspergillosis - Products under Development by Companies - Aspergillosis - Products under Investigation by Universities/Institutes - Aspergillosis - Companies Involved in Therapeutics Development - Amplyx Pharmaceuticals, Inc. - Astellas Pharma Inc. - Aureogen Biosciences, Inc. - Biomar Microbial Technologies - Cidara Therapeutics, Inc. - Eisai Co., Ltd. - F2G Ltd - Globavir Biosciences, Inc. - Hsiri Therapeutics, LLC - iCo Therapeutics Inc. - Merck & Co., Inc. - Nanomerics Ltd - Novabiotics Limited - Pulmocide Ltd - Scynexis, Inc. - Sealife PHARMA GMBH - Sigma-Tau S.p.A. - TGV-Laboratories - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/lx...ergillosis
VICL: 3.25 (+0.06), MRK: 62.96 (-0.06), CDTX: 12.15 (-0.12)
Global Gene Therapy Market Forecast to 2020 - North America Has Maximum Number of Clinical Trials
M2 - Tue Jan 19, 5:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/rd9b7c/global_gene) has announced the addition of the "Global Gene Therapy Market Forecast to 2020" report to their offering. Gene therapy is one of the most widely researched fields in the healthcare industry. The high potential of gene therapy to cure various chronic diseases makes it a popular research area. Various researches are being performed across the globe to explore the potential of gene therapy for the treatment of incurable diseases, such as diabetes, cancer, and HIV amongst others. According to the report, most of the gene therapy researches are being focused on finding the treatment for cancer, followed by genetic diseases and neurological disorders, respectively. In this context, the gene therapy application chapter of the report provides a comprehensive overview of various diseases in which the gene therapy is used, along with the current and future market size of gene therapy for particular disease and its geographical break up. North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Companies Mentioned: - Advantagene Inc. - Bluebird Bio - Genethon - Human Stem Cells Institute - Oxford BioMedica Plc - Sanofi - Shanghai Sunway Biotech Co. Ltd. - Sibiono GeneTech Co. Ltd. - Spark Therapeutics, LLC - Vical Inc. - ViroMed Co. Ltd. dba VM BioPharma - uniQure N.V. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Gene Therapy - An Introduction 4. Industry Overview 5. Clinical Trial Assessment & Pipeline Analysis 6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario 7. Marketed Gene Therapies 8. Global Gene Therapy Market 9. Gene Therapy Market by Application 10. Global Gene Therapy Market Size by Geography 11. Competitive Landscape 12. Key Players Analysis For more information visit http://www.researchandmarkets.com/research/rd...lobal_gene
BLUE: 71.68 (-1.62), VICL: 3.25 (+0.06), ONCE: 60.22 (-1.99)
Vical's VL-2397 Gets Orphan Status for Invasive Aspergillosis
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:50PM CST
Vical's (VICL) antifungal candidate, VL-2397, was granted Orphan Drug designation for the treatment of patients with invasive aspergillosis.
VICL: 3.25 (+0.06), HZNP: 19.43 (+0.02), LGND: 115.78 (-2.38)
Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 3:16PM CDT
Vical (VICL) and Astellas reported disappointing top-line phase II data on cytomegalovirus vaccine candidate, ASP0113, in kidney transplant patients.
VICL: 3.25 (+0.06), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)
Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients
GlobeNewswire - Mon Sep 19, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) and Astellas Pharma Inc. (TOKYO:4503) today announced topline results from a randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety and efficacy of cytomegalovirus (CMV) vaccine, ASP0113, versus placebo in kidney transplant patients receiving an organ from a CMV-seropositive donor. Results from the study demonstrated that the trial did not meet its primary endpoint, which was the proportion of patients having CMV viremia defined as a plasma viral load of greater-than or equal to 1000 IU/mL by central laboratory assay through one year after first injection of study drug. Additionally, the secondary endpoints of CMV-associated disease and CMV-specific antiviral therapy, which were evaluated by an independent, blinded Adjudication Committee, were similar in both treatment groups.
VICL: 3.25 (+0.06)
Vical to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Fri Sep 02, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Monday, September 12, at 11:40 a.m. ET at the 18 Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City. A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 3.25 (+0.06)
Vical Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three and six months ended June 30, 2016. Net loss for the second quarter of 2016 was $1.3 million, or $0.14 per share, compared with a net loss of $2.8 million, or $0.30 per share, for the second quarter of 2015. Revenues for the second quarter of 2016 were $4.1 million, compared with revenues of $4.2 million for the second quarter of 2015, reflecting revenues from Astellas Pharma Inc. for manufacturing services performed under the ASP0113 collaborative agreements. ASP0113 is Vical's therapeutic vaccine designed to prevent cytomegalovirus (CMV) disease and associated complications in transplant recipients.
VICL: 3.25 (+0.06)
Investor Calendar Invites You to the Vical Second Quarter 2016 Earnings Webcast Live on Tuesday, August 9, 2016
ACCESSWIRE - Mon Aug 08, 3:10PM CDT
SAN DIEGO, CA / ACCESSWIRE / August 8, 2016 / Vical Incorporated (NASDAQ: VICL) will host a live webcast to discuss the results of the second quarter 2016, to be held Tuesday, August 9, 2016 at 12:00 PM Eastern Time.
VICL: 3.25 (+0.06)
Vical Announces News Release and Conference Call Schedule for Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 02, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended June 30, 2016, before the opening of trading on Tuesday, August 9, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Tuesday, August 9. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
VICL: 3.25 (+0.06)
Vical Announces $7.8 Million Equity Investment by Partner, AnGes MG
GlobeNewswire - Mon Aug 01, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) announced an agreement by AnGes, MG, Vical's long-time partner and an existing shareholder, to purchase approximately $7.8 million of Vical's common stock in a private placement. The shares are being sold at a price of $4.24 per share, the 90-day volume weighted average price of Vical's common stock and a premium compared to the closing price on July 29. With the new investment, AnGes' equity position in Vical will increase from 2.4% to approximately 18.6% of Vical's outstanding shares. The private placement is expected to close on or about August 2, 2016, subject to the satisfaction or waiver of customary closing conditions.
VICL: 3.25 (+0.06)
Vical (VICL) Reports Phase I/II Data on Genital Herpes Vaccine
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:12AM CDT
Vical (VICL) presented data from a phase I/II study on its investigational genital herpes vaccine at a meeting of the American Society for Microbiology.
VICL: 3.25 (+0.06), ANIP: 66.64 (-0.17), PFE: 34.26 (+0.11), BMY: 56.48 (+0.06)
Vical's Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months
GlobeNewswire - Mon Jun 20, 10:15AM CDT
Vical Incorporated (Nasdaq:VICL) presented data from the randomized, double-blind, placebo-controlled Phase 1/2 clinical trial of its therapeutic genital herpes vaccine in symptomatic herpes simplex virus type 2 (HSV-2) infected patients in an oral late-breaker presentation at the American Society for Microbiology (ASM/ICAAC) Microbe 2016 meeting held in Boston. The slides presented by Mammen P. "Anza" Mammen, Jr., M.D., Vical's Vice President, Clinical Vaccines, will be accessible on Vical's website.
VICL: 3.25 (+0.06)
Vical to Present HSV-2 Phase 1/2 Data at June ASM Microbe/ICAAC 2016 Conference
GlobeNewswire - Mon Jun 13, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) announced today that the company will present clinical data on its completed HSV-2 Phase 1/2 trial at the American Society of Microbiology (ASM) Microbe/ICAAC 2016 conference (Boston, June 16 - 20).
VICL: 3.25 (+0.06)
Vical Provides VL-2397 Updates at BIO International Convention
GlobeNewswire - Tue May 31, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) announced today that the company will present an update on its investigational antifungal product candidate, VL-2397, at the BIO International Convention (San Francisco, June 6 - 9).
VICL: 3.25 (+0.06)
Vical reports 1Q loss
Automated Insights - Mon May 09, 5:36AM CDT
SAN DIEGO (AP) _ Vical Inc. (VICL) on Monday reported a loss of $2.4 million in its first quarter.
VICL: 3.25 (+0.06)
Vical Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 5:30AM CDT
ASP0113 Phase 3 Trial Enrollment Over 80% Complete
VICL: 3.25 (+0.06)
Investor Calendar Invites You to the Vical First Quarter 2016 Earnings Webcast Live on Monday, May 9, 2016
ACCESSWIRE - Fri May 06, 3:05PM CDT
SAN DIEGO, CA / ACCESSWIRE / May 6, 2016 / Vical Incorporated (NASDAQ: VICL) will host a live webcast to discuss the results of the first quarter 2016, to be held Monday, May 9, 2016 at 12:00 PM Eastern Time.
VICL: 3.25 (+0.06)
Vical Announces News Release and Conference Call Schedule for First Quarter 2016 Financial Results
GlobeNewswire - Mon May 02, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2016, before the opening of trading on Monday, May 9, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Monday, May 9. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
VICL: 3.25 (+0.06)
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/d53rgr/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus HHV-5 Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus HHV-5 Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cytomegalovirus HHV-5 Infections Overview - Therapeutics Development - Pipeline Products for Cytomegalovirus HHV-5 Infections - Overview - Pipeline Products for Cytomegalovirus HHV-5 Infections - Comparative Analysis - Cytomegalovirus HHV-5 Infections - Therapeutics under Development by Companies - Cytomegalovirus HHV-5 Infections - Therapeutics under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cytomegalovirus HHV-5 Infections - Products under Development by Companies - Cytomegalovirus HHV-5 Infections - Products under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Atara Biotherapeutics, Inc. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - China Biologic Products, Inc. - CyTuVax B.V. - GlaxoSmithKline Plc - Hookipa Biotech AG - Humabs BioMed SA - iQur Limited - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Savoy Pharmaceuticals, Inc. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/d5...egalovirus
CBPO: 126.09 (+0.87), VICL: 3.25 (+0.06), CMRX: 5.72 (-0.03), PFE: 34.26 (+0.11), MRK: 62.96 (-0.06), ATRA: 20.12 (-0.34), VBIV: 3.90 (+0.09), GSK: 43.42 (-0.16), NVS: 81.48 (-0.55)
Measles - World Therapeutics Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/7nr298/measles) has announced the addition of the "Measles - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Measles, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Measles and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Measles Overview - Therapeutics Development - Pipeline Products for Measles - Overview - Pipeline Products for Measles - Comparative Analysis - Measles - Therapeutics under Development by Companies - Measles - Therapeutics under Investigation by Universities/Institutes - Measles - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Measles - Products under Development by Companies - Measles - Products under Investigation by Universities/Institutes - Measles - Companies Involved in Therapeutics Development - Beijing Minhai Biotechnology Co., Ltd - Beijing Tiantan Biological Products Co., Ltd. - Biological E. Limited - China National Pharmaceutical Group Corporation - Daiichi Sankyo Company, Limited - GlaxoSmithKline Plc - Organic Vaccines - Prometheon Pharma, LLC - Sinovac Biotech Ltd. - Vical Incorporated - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/7nr298/measles
VICL: 3.25 (+0.06), GSK: 43.42 (-0.16), SVA: 5.81 (-0.06)
Aspergillosis Market Report - Global Therapeutics Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/lxqfdm/aspergillosis) has announced the addition of the "Aspergillosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Aspergillosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aspergillosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Aspergillosis Overview - Therapeutics Development - Pipeline Products for Aspergillosis - Overview - Pipeline Products for Aspergillosis - Comparative Analysis - Aspergillosis - Therapeutics under Development by Companies - Aspergillosis - Therapeutics under Investigation by Universities/Institutes - Aspergillosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Aspergillosis - Products under Development by Companies - Aspergillosis - Products under Investigation by Universities/Institutes - Aspergillosis - Companies Involved in Therapeutics Development - Amplyx Pharmaceuticals, Inc. - Astellas Pharma Inc. - Aureogen Biosciences, Inc. - Biomar Microbial Technologies - Cidara Therapeutics, Inc. - Eisai Co., Ltd. - F2G Ltd - Globavir Biosciences, Inc. - Hsiri Therapeutics, LLC - iCo Therapeutics Inc. - Merck & Co., Inc. - Nanomerics Ltd - Novabiotics Limited - Pulmocide Ltd - Scynexis, Inc. - Sealife PHARMA GMBH - Sigma-Tau S.p.A. - TGV-Laboratories - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/lx...ergillosis
VICL: 3.25 (+0.06), MRK: 62.96 (-0.06), CDTX: 12.15 (-0.12)
Global Gene Therapy Market Forecast to 2020 - North America Has Maximum Number of Clinical Trials
M2 - Tue Jan 19, 5:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/rd9b7c/global_gene) has announced the addition of the "Global Gene Therapy Market Forecast to 2020" report to their offering. Gene therapy is one of the most widely researched fields in the healthcare industry. The high potential of gene therapy to cure various chronic diseases makes it a popular research area. Various researches are being performed across the globe to explore the potential of gene therapy for the treatment of incurable diseases, such as diabetes, cancer, and HIV amongst others. According to the report, most of the gene therapy researches are being focused on finding the treatment for cancer, followed by genetic diseases and neurological disorders, respectively. In this context, the gene therapy application chapter of the report provides a comprehensive overview of various diseases in which the gene therapy is used, along with the current and future market size of gene therapy for particular disease and its geographical break up. North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Companies Mentioned: - Advantagene Inc. - Bluebird Bio - Genethon - Human Stem Cells Institute - Oxford BioMedica Plc - Sanofi - Shanghai Sunway Biotech Co. Ltd. - Sibiono GeneTech Co. Ltd. - Spark Therapeutics, LLC - Vical Inc. - ViroMed Co. Ltd. dba VM BioPharma - uniQure N.V. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Gene Therapy - An Introduction 4. Industry Overview 5. Clinical Trial Assessment & Pipeline Analysis 6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario 7. Marketed Gene Therapies 8. Global Gene Therapy Market 9. Gene Therapy Market by Application 10. Global Gene Therapy Market Size by Geography 11. Competitive Landscape 12. Key Players Analysis For more information visit http://www.researchandmarkets.com/research/rd...lobal_gene
BLUE: 71.68 (-1.62), VICL: 3.25 (+0.06), ONCE: 60.22 (-1.99)
Vical's VL-2397 Gets Orphan Status for Invasive Aspergillosis
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:50PM CST
Vical's (VICL) antifungal candidate, VL-2397, was granted Orphan Drug designation for the treatment of patients with invasive aspergillosis.
VICL: 3.25 (+0.06), HZNP: 19.43 (+0.02), LGND: 115.78 (-2.38)
